Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Rocket Pharmaceuticals, Inc. (RCKT : NSDQ)

• Company Description    Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company. It focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket Pharmaceuticals Inc., formerly known as Inotek Pharmaceuticals Corporation, is based in LEXINGTON, United States. Number of Employees: 299

• Price / Volume Information    Yesterday's Closing Price: $3.94 Daily Weekly Monthly 20 Day Moving Average: 3,119,167 shares Shares Outstanding: 107.90 (millions) Market Capitalization: $425.14 (millions) Beta: 0.60 52 Week High: $18.17 52 Week Low: $2.19 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 20.12% 16.38% 12 Week 28.34% 18.16% Year To Date -68.66% -73.18%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 9 Cedarbrook Drive - Cranbury,NJ 08512 USA ph: 609-659-8001 fax: 646-224-9585 mdodge@rocketpharma.com http://www.rocketpharma.com

• General Corporate Information    Officers Gaurav Shah - Chief Executive Officer and Director Aaron Ondrey - Chief Financial Officer John Militello - Vice President; Finance; Senior Controller Elisabeth Bjork - Director Carsten Boess - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 77313F106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 107.90 Most Recent Split Date: 1.00 (0.25:1) Beta: 0.60 Market Capitalization: $425.14 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.44 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.06 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 25.47% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.19 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 20.27% vs. Previous Quarter: -5.36% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -65.11 03/31/25 - -64.92 ROA 09/30/25 - - 06/30/25 - -55.99 03/31/25 - -56.13 Current Ratio 09/30/25 - - 06/30/25 - 6.39 03/31/25 - 9.19 Quick Ratio 09/30/25 - - 06/30/25 - 6.39 03/31/25 - 9.19 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 3.32 03/31/25 - 3.86 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.05 03/31/25 - 0.05 Debt-to-Capital 09/30/25 - - 06/30/25 - 5.19 03/31/25 - 4.49

Powered by Zacks Investment Research ©